ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0010

Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19

Matthew Woodruff1, Richard Ramonell2, Ankur Singh Saini2, Mark Rudolph3, F. Eun-Hyung Lee2 and Iñaki Sanz4, 1Emory University, Decatur, GA, 2Emory University, Atlanta, GA, 3Exagen Inc., Vista, CA, 4Emory University School of Medicine, Atlanta, GA

Meeting: ACR Convergence 2021

Keywords: Autoantibody(ies), B-Lymphocyte, COVID-19, immunology, Infection

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (0001–0010)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: An emerging feature of COVID-19 is the identification of autoreactivity in patients with severe disease that may contribute to disease pathology, however the origins of these responses remain unclear. Previously, we identified extrafollicular B cell activation as a shared immune feature between severe COVID-19 and active rheumatic disease. In autoimmune settings, this pathway is associated with relaxed peripheral tolerance in the antibody secreting cell compartment and the generation of de novo autoreactive responses.

Methods: To further investigate these responses in COVID-19, we performed single-cell B-cell repertoire analysis on 7 patients with severe disease to understand the nature of the antibody secreting cell compartment. We paired these data with cytometry-based and serological assays to detail the nature of these cells, and their contribution to antiviral, and autoreactive responses.

Results: In these patients, we identify a unique low-mutation IgG1 fraction of the antibody secreting cell compartment that lacks surface-expressed B cell receptor, and thus cannot be studied through traditional antigen-labeling studies. These cells are not memory derived, display very low levels of selective pressure, and are enriched for autoreactivity-prone V gene IGHV4-34. Within this compartment, we identify B cell lineages that display specificity to both SARS-CoV-2 and autoantigens, and describe progressive, broad, clinically relevant autoreactivity within these patients including emerging reactivity against the glomerular basement membrane. While progressive early in acute infection, we identify the contraction of this pathway 6 months post-recovery, and a re-establishment of tolerance standards coupled with a concomitant loss of acute-derived responders irrespective of antigen specificity.

Conclusion: In total, this study reveals the origins, breadth, and resolution of emerging autoreactivity in severe COVID-19, with significant implications in both acute-phase rheumatologic interventions and potential treatment of patients with post-COVID sequelae.


Disclosures: M. Woodruff, None; R. Ramonell, None; A. Singh Saini, None; M. Rudolph, Exagen, Inc, 3, 11; F. Lee, MicoBPlex, 8; I. Sanz, None.

To cite this abstract in AMA style:

Woodruff M, Ramonell R, Singh Saini A, Rudolph M, Lee F, Sanz I. Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19 [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/relaxed-peripheral-tolerance-drives-broad-de-novo-autoreactivity-in-severe-covid-19/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/relaxed-peripheral-tolerance-drives-broad-de-novo-autoreactivity-in-severe-covid-19/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology